Vnitr Lek 2009, 55(Suppl 1):48-51

Current advances in the care for patients with haemophilia

M. Penka1,3,*, J. Blatný1,3, M. Matýšková1,3, P. Smejkal1,3, E. Tesařová2,3
1 Oddělení klinické hematologie FN Brno, pracoviště Bohunice, přednosta prof. MUDr. Miroslav Penka, CSc.
2 Transfuzní oddělení a krevní banka FN Brno, pracoviště Bohunice, přednostka prim. MUDr. Eva Tesařová
3 Univerzitní centrum pro trombózu a hemostázu Masarykovy univerzity Brno

Haemophilia is a disease known from antiquity and always stirring significant expert and lay discussion. This is an infrequent disease that, nevertheless, is characterized by certain regularities that have rather unusual but often paradigmatic nature. Non-medical issues, at present in particular, are predominantly financial. It is, therefore, necessary to address the issue of haemophilia in detail and to attempt to provide comprehensive solutions based on seamless organization and clear definitions of the character and extent of care as well as on rational utilization of all available resources provided by the current medicine and age. The paper reviews development of the care for haemophilia patients in the past and up to the present time.

Keywords: haemophilia; substitution; CCC, HTC; multi-professional care

Received: April 15, 2009; Published: February 1, 2009  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Penka M, Blatný J, Matýšková M, Smejkal P, Tesařová E. Current advances in the care for patients with haemophilia. Vnitr Lek. 2009;55(Supplementum 1):48-51.
Download citation

References

  1. Blatný J. Inhereted coagulation disorders (Vrozené trombofilní stavy). In: Starý J et al (eds). Dětská hematologie. Trendy soudobé pediatrie, svazek 4. Praha: Galén 2005: 189-203.
  2. Blatny J, Kohlerova S, Komrska V et al. Bleeding Prophylaxis in Children with Haemophilia A/B Using Plasma-derived Concentrates Immunate/Immunine - Prospective Survey. J Thromb Haemost 2005; 3 (Suppl 1): Abstract P 1998.
  3. Blatny J, Kohlerova S, Zapletal O et al. Prophylaxis with recombinant factor VIIa for the management of bleeding episodes during immune tolerance treatment in a boy with severe haemophilia A and high-response inhibitors. Haemophilia 2008; 14: 1140-1142. Go to original source... Go to PubMed...
  4. Bozděch Z, R.Moster J, Stryhal J et al. Totální protéza kolenního kloubu u hemofiliků. Acta Chir Orthop Traum Čech 1983; 50: 228-233. Go to PubMed...
  5. Colvin BT, Astermark J, Fischer K et al. Inter Disciplinary Working Group. European principles of haemophilia care. Haemophilia 2008; 14: 361-374. Go to original source... Go to PubMed...
  6. Husa P, Roznovský L, Smejkal P et al. Efficacy and safety of chronic hepatitis C treatment in haemophilic patients. Hepatogastroenterology 2005; 52: 1541-1544. Go to PubMed...
  7. Matýšková M, Penka M. Hemofilie. Vnitř Lék 1991; 37: 397-403. Go to PubMed...
  8. Morfini M, Auerswald G, Kobelt RA et al. Prophylactic treatment of haemophilia patients with inhibitors: clinical experience with recombinant factor VIIa in European Haemophilia Centres. Haemophilia 2007; 13: 502-507. Go to original source... Go to PubMed...
  9. Moster R, Penka M, Matěja F. Operační léčba pohybového aparátu u krvácivých stavů. Acta Chir Orthop Traum Čech 1986; 53: 54-61. Go to PubMed...
  10. Penka M, Smejkal P, Buliková A et al. Multiple Orthopaedic procedures in Hemophiliac Patients. Reports from the 17th International Congress on Thrombosis, Invited reports to Symposia, Monduzi editore, Internationak Proceedings Division, Bologna, Italy, Oct 2002, 63-66.
  11. Penka M, Dušek L, Smejkal P et al. Project HemIS (Haemophilia-Information System): multicentric information system of evaluation of clinical data of patients with haemophilia. Haemophilia 2004; 10 (Suppl 3): 21-22.
  12. Penka M. Vrozené krvácivé stavy. In: Indrák K et al (eds). Hematologie. Vnitřní lékařství - postgraduální klinická project. Praha: Triton 2006/2007: 110-117.
  13. Salaj P, Brabec P, Penka M et al. Effect of rFVIIa dose and time to treatment on patients with haemophilia and inhibitors: Analysis of HemoRec Registry data from the Czech Republic. Haemophilia 2009; 15: 752-759. Go to original source... Go to PubMed...
  14. Smejkal P, Mužík J, Penka M et al. The use of FEIBA® and NovoSeven® for treatment of bleeding episodes in patients with hemophilia A and factor VIII inhibitor: a single centre experience. Haematologica 2006; 91 (Suppl 1): 156-157.
  15. Smejkal P, Matýšková M, Penka M. Hemofilie. Vnitř Lék 2008; 54: 992-999. Go to PubMed...
  16. Smejkal P, Matyskova M, Chlupova G et al. Haemophilia patients in South Moravia: Survey of the preceeding 20 years. Hämostaseologie 2008; 28 (Suppl 1): 21-23. Go to original source... Go to PubMed...




Vnitřní lékařství

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.